A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Inclusion Criteria

• •Histologically confirmed operable or inoperable invasive Stage II-III BC according to American Joint Committee on Cancer (AJCC) TNM staging classification
• •Candidate for neoadjuvant treatment and considered appropriate for endocrine combination therapy
• •Willingness to undergo breast surgery (mastectomy or breast-conserving surgery) after neoadjuvant treatment (unless inoperable)
• •Documented ER-positive tumor in accordance with current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
• •Documented HER2-negative tumor in accordance with current ASCO/CAP guidelines
• •Documented Ki-67 score \>=5% as per local assessment
• •Confirmed PIK3CA mutation